In Law360, Brad Flint Examines Biotechnology Financing and Deal Strategies as Election Day Approaches

In a Law360 article, emerging companies and venture capital partner and practice co-lead Brad Flint examined the financing and growth strategies for private biotechnology companies. As Election Day approaches, companies are more focused on the first quarter of 2025 for the initial public offering (IPO) window reopening.

Brad notes that acquiring companies are being selective, carefully measuring the clinical data of potential biotechnology targets before proceeding with a buyout.

He is seeing smaller, venture-backed companies merge with one another as a way of efficiently combining assets. Given the challenging fundraising conditions in private markets, some biotech startups are returning to previous investors to complete "bridge rounds" that could satisfy their capital needs until markets recover.